Biblio

Nardin C., Cordonnier M., Chanteloup G., Derangere V., Algros M., Arnould L., Garrido C., Aubin F., Gobbo J..  2019.  Circulating PD-L1-exosomes to monitor tumor response in melanoma patients. JOURNAL OF INVESTIGATIVE DERMATOLOGY. 139:S304.

Nardin C, Cordonnier M, Chanteloup G, Derangere V, Algros MPaule, Marcion G, Arnould L, Garrido C, Aubin F, Gobbo J.  2019.  Circulating PD-L1-exosomes to monitor tumor response in melanoma patients.. JOURNAL OF CLINICAL ONCOLOGY. 37

Bidard F-C, Kiavue N, Ychou M, Cabel L, Stern M-H, Madic J, Saliou A, Rampanou A, Decraene C, Bouche O et al..  2019.  Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. CELLS. 8

Bidard F-C, Jacot W, Dureau S, Brain E, Bachelot T, Bourgeois H, Goncalves A, Ladoire S, Naman H, Dalenc F et al..  2019.  Circulating tumor cells as a tool to guide first line therapy in metastatic breast cancer: subgroup analyses of the STIC CTC Phase III utility trial. CANCER RESEARCH. 79

T. Rouge DLa Motte, Cottu P., Pautier P., Provansal M., Floquet A., Selle F., Fabbro M., Kalbacher E., Follana P., Lesoin A.F et al..  2017.  Circulating tumor cells as prognostic marker in ovarian carcinoma: Results from the ANTHALYA study. ANNALS OF ONCOLOGY. 28

Pierga J-Y, Vaucher I, Gutierrez M, Tredan O, Guiu S, Romieu G, Goncalves A, Debled M, Levy C, Ferrero J-M et al..  2015.  Circulating tumor cells (CTC) and endothelial cells (CEC) changes in HER2 negative metastatic breast cancer (MBC) patients treated with first line weekly paclitaxel and bevacizumab: Preliminary results of a prospective cohort from the French Breast Cancer. CANCER RESEARCH. 75

Pierga J-Y, Tredant O., Chevrier M., Dubot C., Lorgis V., Romieu G., Goncalves A., Debled M., Levy C., Ferrero J-M et al..  2017.  Circulating tumor cells (CTC) and endothelial cells (CEC) prognostic value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: First results of a prospective cohort from the French Breast Cancer In. CANCER RESEARCH. 77

Cottu P., T. Rouge DLa Motte, Pautier P., Provansal M., Floquet A., Selle F., Mouret-Reynier M.A, Fabbro M., Kalbacher E., Piprot C. et al..  2015.  Circulating tumor cells kinetics in ovarian carcinoma: correlation with baseline characteristics and CA-125 levels in the randomized ANTHALYA trial evaluating bevacizumab in the neoadjuvant setting. EUROPEAN JOURNAL OF CANCER. 51:S555.

Ortiz-Cuaran S., Mezquita L., Swalduz A., Aldea M., Mazieres J., Jovelet C., Flores W.RChumbi, Lacroix L., Loriot Y., Friboulet L. et al..  2019.  Circulating Tumor DNA Analysis Depicts Potential Mechanisms of Resistance to BRAF-Targeted Therapies in BRAF plus Non-Small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY. 14:S337.

Bidard F-C., Ychou M., Madic J., Saliou A., Bouche O., Rivoire M., Ghiringhelli F., Francois E., Guimbaud R., Mineur L. et al..  2016.  Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial. ANNALS OF ONCOLOGY. 27

Pierga J-Y, Silveira A., Lorgis V., Tanguy M-L, Tredan O., Dubot C., Jacot W., Goncalves A., Debled M., Levy C. et al..  2019.  Circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) predictive value in HER2 negative metastatic breast cancer patients treated with first line weekly paclitaxel and bevacizumab: Results of a prospective cohort from the French Breast Cancer In. CANCER RESEARCH. 79

Ortiz-Cuaran S, Mezquita L, Swalduz A, Aldea M, Mazieres J, Leonce C, Jovelet C, Pradines A, Avrillon V, Flores WRChumbi et al..  2020.  Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 26:6242-6253.

Kurtz DM, Scherer F, Jin MC, Soo J, Craig AFM, Esfahani MShahrokh, Chabon JJ, Stehr H, Liu CLong, Tibshirani R et al..  2018.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY. 36:2845+.

Harper L, Blanc T., Peycelon M., Michel J.L, Leclair M.D, Garnier S., Flaum V, Arnaud A.P, Merrot T., Dobremez E. et al..  2022.  Circumcision and Risk of Febrile Urinary Tract Infection in Boys with Posterior Urethral Valves: Result of the CIRCUP Randomized Trial. EUROPEAN UROLOGY. 81:64-72.

Wendling D, Chouk M, Guillot X, Aubry S, Prati C.  2021.  Circumscribed myositis ossificans. JOINT BONE SPINE. 88:105119.

Thabut D, Pauwels A, Carbonell N, Remy AJean, Nahon P, Causse X, Cervoni J-P, Cadranel J-F, Archambeaud I, Bramli S et al..  2018.  Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: A large multicentre audit with real-life results. JOURNAL OF HEPATOLOGY. 68:73-81.

Vanbervliet-Defrance B, Delaunay T, Daunizeau T, Kepenekian V, Glehen O, Weber K, Estornes Y, Ziverec A, Djemal L, Delphin M et al..  2020.  Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma. CANCER LETTERS. 472:29-39.

Boustani J, Joseph ELauret Mar, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N et al..  2021.  Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood. BMC IMMUNOLOGY. 22:38.

Fiteni F, Nguyen T, Vernerey D, Paillard M-J, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X.  2014.  Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. CANCER MEDICINE. 3:1502-1511.

Rey C.  2019.  Cistercians and the transmission of texts (XIII-XVIII centuries). CAHIERS DE CIVILISATION MEDIEVALE. 62:190-193.

Rey C.  2019.  Cistercians and the transmission of texts (XIII-XVIII centuries). CAHIERS DE CIVILISATION MEDIEVALE. 62:190-193.

Frame A.  2016.  Citizen Participation and Political Communication in a Digital World Introduction. CITIZEN PARTICIPATION AND POLITICAL COMMUNICATION IN A DIGITAL WORLD. 32:1-10.

Frame A.  2016.  Citizen Participation and Political Communication in a Digital World Introduction. CITIZEN PARTICIPATION AND POLITICAL COMMUNICATION IN A DIGITAL WORLD. 32:1-10.

Gonzales A.  2018.  CITIZENSHIP, UNIVERSALISM AND STOIC COSMOPOLITANISM: THE ROMAN CASE. ARYS-ANTIGUEDAD RELIGIONES Y SOCIEDADES. 16:19-45.

Chenevez A.  2020.  The City Shaped by the Rhetoric of Heritage: Imagining Standardization Away. URBANITIES-JOURNAL OF URBAN ETHNOGRAPHY. 10:40-52.